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Abstract Prostaglandin E2 (PGE2) is regarded as a potent 
regulator of the immune system. It can regulate apoptosis in 
mononuclear cells and modulate the cytokine secretion pattern 
from T-helper cell subpopulations via an increase in cyclic AMP 
(cAMP). Of the 4 PGE2 receptor subtypes (EPI-EP4) that are 
defined pharmacologically by their affinity to subtype-specific 
ligands and their coupling to G proteins, EP2 and EP4 receptors 
couple to Gs. It is as yet unknown which of these two receptor 
subtypes mediates the immunomodulatory effects. By quantita- 
tive RT-PCR, the mRNA for EP4 receptors was demonstrated 
and quantified in the human mononuclear cell lines Jurkat, KM- 
3 and U-937. However, EP2 receptor mRNA was only present in 
U-937 cells and was 100-fold less abundant than EP4 receptor 
mRNA. PGE2 increased cAMP formation with an EDs0 of 50- 
100 nM in all cell lines, cAMP formation was inhibited by the 
EP4R-specific antagonist AH23848. Since AH23848 inhibited 
PGE2-induced cAMP formation in U-937 cells to a similar 
extent as in Jurkat and KM-3, EP2 receptors seem to play, if 
any, only a secondary role for the PGE2-mediated cAMP 
formation in U-937 cells. 
Key words. Prostaglandin E2 receptor; Cyclic AMP; 
Immunomodulation; Quantitative r verse transcription 
polymerase chain reaction 
1. Introduction 
Prostaglandin receptors belong to the RVG class of recep- 
tors, They consist of an extracellular N-terminal domain, 7 
transmembrane domains, 3 extracellular and 3 intracellular 
loops and the intracellular C-terminal domain. They are 
coupled to heterotrimeric G proteins, which mediate signalling 
by second messengers like cyclic AMP (cAMP) or InsP3/Ca 2+. 
According to their affinity to various agonists and antagonists 
and their coupling to different G proteins, receptors for PGE2 
can by divided into four subtypes (EPI-EP4) [1]. Of these, the 
EPI receptor utilizes InsPJCa 2+ as a second messenger, while 
the others modulate intracellular cAMP. The EP3 receptors 
decrease cAMP by inhibiting adenylate cyclase through a Gi 
protein, the EP2 and EP4 receptors increase cAMP by acti- 
vating adenylate cyclase through a Gs protein. 
PGE2 has been suggested to be a modulator of the immune 
system. It can modulate cytokine secretion from T-helper lym- 
phocyte subsets, termed Thl and Th2 [2]. Thl cells secrete 
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certain cytokines like IL-2 and IFN- 7, which stimulate cyto- 
toxic T-lymphocytes, whereas Th2 cells secrete mainly IL-4 
and IL-10 and thereby stimulate B-lymphocytes. The cyto- 
kines secreted by Thl cells can inhibit Th2 cells and vice versa 
[3,4]. PGE2 can suppress cytokine secretion of Thl cells while 
cytokine secretion of Th2 cells remains unchanged or is even 
enhanced [5]. Therefore, PGE2 can shift the balance of the 
immune system in favor of a humoral over a cell-mediated 
immune response. Furthermore, PGE2 supports the class 
switch from IgM to IgE in B-lymphocytes [6,7]. Finally, it 
can modulate agonist-induced apoptosis in T- and B-lympho- 
cytes [8-10]. It is as yet unknown by which type of PGE2 
receptor these effects are mediated. Some of the immunomod- 
ulatory effects could be mimicked by raising intracellular 
cAMP through cholera toxin, forskolin or dibutyryl cAMP 
[6,11,12]. It therefore seems likely that the immunomodula- 
tory effects of PGE2 are mediated by the Gs-coupled EP2 
and/or EP4 receptors. 
The study of PGE2 receptors on mononuclear cells by bind- 
ing and functional studies has been hampered by the fact that 
binding characteristics of the PGE2 receptor subtypes are very 
similar. The subtype specificity of 'selective' agonists and an- 
tagonists is limited and usually more than one type of pros- 
tanoid receptor or even PGE2 receptor is present on the same 
cell. It is essentially impossible to differentiate between the 
multiple binding sites in a population. Especially low abun- 
dance sites might be missed. Only a few copies of PGE2 re- 
ceptors are present per cell [13 16]. The corresponding 
mRNAs are of low abundance and therefore hard to quantify 
by Northern blot techniques. Instead, a competitive reverse 
transcription polymerase chain reaction (RT-PCR) was used 
here as a highly sensitive method to demonstrate and quantify 
subtype specific receptor mRNAs in established human mono- 
nuclear cell lines as models for monocytes as well as B- and T- 
lymphocytes. 
2. Materials and methods 
2~ 1. Cell lines and culture 
The established human cell lines Jurkat, KM-3 and U-937 were 
continuously cultured in suspension ata density of 0.5 2× 10 6 cells/ 
ml in medium containing 80% RPMI-1640 (Gibco, Eggenstein, Ger- 
many) and 20°/,, M199 (Gibco). To this mixture 10% heat-inactivated 
fetal calf serum was added. 
2.2. Stimulation of cAMP generation by PGE2 and its inhibition by 
AH23848 in membrane preparations 
Cells were lysed in 5 mM Tris-HCl (pH 7.4)12 mM EDTA at 5><: 10 6 
cells/ml with a rotor/stator homogenizer four times 5 s on ice. The 
homogenate was centrifuged for 2 min at 800×g at 4°C and the 
supernatant centrifuged at 100000×g for 1 h at 4°C. The crude 
membrane pellet was resuspended in 75 mM Tris-HC1 (pH 7.4), 25 
0014-5793/96l$12.00 (© 1996 Federation of European Biochemical Societies. All rights reserved. 
PH SO0 1 4-5793(96)00928-3  
40 
mM MgCI2, 2 mM EDTA and aliquots frozen at -70°C until further 
use. 
An aliquot representing 25 ~tg of crude membrane protein was 
preincubated with AH23848 (Glaxo, UK, final concentration 25 
~tM) in 6% ethanol or plain 6% ethanol as control on ice for 10 
min. PGE2 was added at final concentrations from 10 nM to 10 
~M and the incubation was continued for 10 min at 37°C. Samples 
were then incubated at 95°C for 5 min and stored at -20°C until 
detection of cAMP by radioimmunoassay (Amersham, Braunschweig, 
Germany). 
2.3. Quantification of cell proliferation 
On day 1, 1 × 104 cells were seeded in 100 ~tl culture medium in 
triplicate into a 96-well tissue culture plate (Sarstedt, Niimbrecht, 
Germany). PGE2 was added every 8 h at final concentrations of
1 nM to 100 ~tM. On day 3, cell proliferation was determined by 
measuring the incorporation of 5-bromo-2'-deoxyuridine (BrdU) 
into the DNA of proliferating cells by ELISA (Boehringer Mannheim, 
Mannheim, Germany). Tests were performed according to the instruc- 
tions of the manufacturer. 
2.4. RNA isolation and cDNA synthesis by reverse transcription 
Total RNA was extracted from approximately 20×106 cells by 
homogenization i  guanidinium isothiocyanate, followed by cesium 
chloride gradient ultracentrifugation [17]. Total RNA concentration 
was determined spectrophotometrically, mRNA was isolated from 
roughly 50 ~g total RNA by oligo-dT affinity chromatography (Qia- 
gen, Hilden, Germany). For cDNA synthesis, the mRNA eluate was 
preincubated with oligo-d(T)12 18 and transcribed with reverse tran- 
scriptase (RT) (Superscript II, Gibco) into cDNA in 30 ~tl buffer. The 
reaction was terminated by heating to 80°C for 5 min; then 30 ~al of 
deionized water was added. Of this solution, 1 p.l (representing about 
16 ng cDNA) was taken for PCR. 
To monitor the efficiency of cDNA synthesis, 1 /aCi of [35S]dATP 
(1000 Ci/mmol, ICN Pharmaceuticals, Eschwege, Germany) was in- 
cluded in the RT mix. The cDNA was precipitated with ammonium 
acetate/ethanol, washed 3 times with 70% ethanol and resuspended in 
30 /.tl deionized water. The radioactivity in the final precipitate was 
proportional to the initial amount of mRNA and therefore represents 
the amount of newly synthesized cDNA. Equal amounts of radio- 
activity from the different RT reactions were taken for quantitative 
PCR. 
2.5. PCR detection of EP2 receptor and EP4 receptor cDNA 
PCR was carried out in a 50 l.tl reaction mix consisting of 0.75 gM 
of each forward and reverse oligonucleotide primer (Table 1), 1.5 mM 
MgCI2, 0.2 mM of each of the four deoxynucleotide triphosphates 
(dNTPs), 6% DMSO (only for EP4R), 1 tll of cDNA preparation 
and 0.25 U of thermostable DNA polymerase (Goldstar Red, Euro- 
gentec, Seraing, Belgium). The cDNA was denatured for 3 min at 
95°C and then subjected to 35 cycles of 1 rain at 95°C, 1 rain at 
60°C for EP2R or 63°C for EP4R and 2 min at 72°C. A final elonga- 
tion step was carried out for 10 min at 72°C. EP2R and EP4R PCR 
products were cloned into the plasmid vector pBlueScript (pBS) and 
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sequenced for identification using dyedeoxy terminator NTPs (Perkin 
Elmer, Weiterstadt, Germany). 
2.6. Generation of internal PCR standards for the EP2 and EP4 
receptors 
A 930 bp RT-PCR fragment of the EP4 receptor [18] (primers EP4- 
3F and -2R) and a 1149 bp fragment of the EP2 receptor [19] (primers 
EP2-3F and -2R) were cloned into the Smal restriction site of pBlue- 
Script. From the construct containing the EP4R insert, a 171 bp 
fragment was removed by restriction enzyme digestion with BssHlI 
(at positions 1037 and 1208, GenBank accession umber L25124), 
followed by gel electrophoresis, extraction (Genomed, Bad Oeynhau- 
sen, Germany) and religation of the new construct. Similarly, a 186 bp 
fragment was deleted from the EP2R construct by Sinai digestion 
(positions 703 and 889, GenBank accession umber U19487). The 
shortened inserts (termed internal standards) were isolated by restric- 
tion enzyme digestion of the flanking polylinker egion with EcoRI 
and BamHI and purified by agarose gel electrophoresis and extrac- 
tion. The concentrations of the extracted standards were determined 
and 10-fold dilution series were prepared, ranging from 500 amol/l.tl to 
0.0005 amol/lal in deionized water containing 50 ng/ml glycogen. 
2.7. Quantitative PCR for EP2R and EP4R cDNA 
For quantitative PCR, 2 [al of the dilution series of the internal 
standards was coamplified with a constant amount of test sample 
cDNA. Aliquots representing equal numbers of counts and therefore 
equal amounts of test sample cDNA from different preparations were 
used to ensure an equal cDNA load in the PCR reaction. After am- 
plification, PCR products were separated and visualized on a 1% 
agarose gel. 
3. Results and discussion 
3.1. RT-PCR detection o f  EP2 and EP4 receptor mRNA in 
human mononuclear cell lines 
PGE~ receptors are expressed on human lymphocytes at 
low copy number;  some cells express more than one type of 
PGE2 receptor, rendering analysis of cellular receptor equip- 
ment by binding studies with synthetic ligands and [3H]PGE2 
difficult [13 16]. With the cloning of the human EP2 and EP4 
receptors, molecular analysis with highly sensitive methods 
like RT-PCR has become possible. Therefore, this method 
was used to study receptor expression in the human cell lines 
Jurkat, KM-3 and U-937 as models for human T- and B- 
lymphocytes and monocytes, respectively. 
After RT-PCR amplification, cDNA for [3-actin was ob- 
served in all three cell lines, indicating successful cDNA syn- 
thesis (Fig. 1). In a control setup, no transcripts were obtained 
with mock transcribed mRNA,  indicating that PCR products 
Table 1 
Oligonucleotide primers used for RT-PCR 
Name Sequence (5 '~ 3') Position GenBank accession umber 
EP2-1F ctc tga gtc tcg gaa cgc tcc agc tc 64-89 U19487 
EP2-2R cat ttc tcc agg gaa caa ttt c 1305-1284 
EP2-3F atg ggc aat gcc tcc aat gac tcc cag 157 183 
EP2-4R tgg cga aag cga agt agg tgc acg cgc 502-476 
EP4-1F atg aag ggc caa tgg ccc ggg ggc cag 82(~852 
EP4-2R ctc ggc gcc cgc gat gcg gcg gaa gc 1386-1361 
EP4-3F gtg aaa gca ggt tgg agg cgg gtc cag 457-483 
EP4-4R cag gat ttt ata agg gtc cag aaa cag 2102 2076 
~-actin F gtg ggc cgc tct agg cac ca 25-44 
~-actin R cgg ttg gcc tta ggg ttc agg ggg g 270 245 
L25124 
M12481 
Primers were designed for the human EP2 and EP4 receptors. Given are the primer positions in the published sequences. Mouse I~-actin primers, 
which also serve to amplify a cDNA fragment of human 13-actin (positions 144-163 and 364-388 in GenBank J00074), were purchased from 
Stratagene (La Jolla, CA, USA). 
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Fig. 1. Detection of mRNA for the EP2 and EP4 receptors in Jur- 
kat, KM-3 and U-937 cells by RT-PCR. eDNA pepared from 
mRNA by reverse transcription was subjected to 35 cycles of PCR 
in the presence of sequence specific primers for the EP2 (primers 
EP2-3F/EP2-2R, 1149 bp) and EP4 receptor (primers EP4-3F/EP4- 
4R, 1648 bp) and ~-actin 1245 bp). 
truly reflect cDNA transcripts and are not due to genomic 
DNA contamination (data not shown). All PCR reactions 
were prepared as master mixes before the addition of cDNA 
and oligonucleotide primers, and the same cDNA was used 
for the detection of EP2 and EP4 receptor mRNA. While the 
mRNA of the EP4 receptor was found in all cell lines, the 
mRNA of the EP2 receptor could only be detected in U-937 
cells (Fig. 1). To exclude that EP2 receptor mRNA was 
missed because of ineffective reverse transcription or PCR, 
cDNA prepared from mRNA of human placenta, from which 
the EP2 receptor was originally cloned, served as a positive 
control (data not shown). 
Receptors of the EP1, 3 and 4 subtypes but not of the EP2 
subtype have recently been described on murine B-lymphocyt- 
ic cell lines by molecular analysis [20]. Although EP2 recep- 
tors were not demonstrated directly, their presence was pos- 
tulated on immature, but not on mature B-cell lines from 
functional studies with various prostaglandin analogues. In 
the present study, mRNA of the cloned human EP2 subtype 
receptor could not be demonstrated in the immature, pre-B- 
lymphoblastic cell line KM-3 by RT-PCR (Fig. 1), although 
this method is far more sensitive. These findings are further 
supported by the detection of mRNA of the EP4, but not of 
the EP2 receptor in various other T- and B-lymphocytic cell 
lines (CEM, HUT78, Raji, Daudi, Wi-L2 and H2LCL, own 
data not shown). It is therefore possible that human and 
murine B-cell lines differ with respect o the expression of 
EP2 receptors. 
3.2. Validation of quantitative competitive RT-PCR and the 
quantitation of mRNA for the EP2 and EP4 receptor in 
human mononuclear cell lines 
RT-PCR is not only a sensitive tool for the qualitative 
detection of mRNA, it can also be used for mRNA quantifi- 
cation when certain important prerequisites are met [21,22]. 
Due to the exponential nature of the amplification process, 
small differences in either the amount of initial cDNA or the 
efficiency of the amplification process can lead to significant 
differences in product quantity. Therefore, for the comparison 
of mRNA levels in different samples, equal amounts of initial 
cDNA, i.e. identical amounts of radioactivity of the reverse 
transcription i  the presence of [aSS]dATP, were used and 
possible differences in the amplification efficiency were ac- 
counted for by the use of a second eDNA template coampli- 
fled in the same reaction. Since amplification efficiency cru- 
cially depends on the oligonucleotide primers but only to a 
negligible xtent on the amplified sequence [21], an internal 
eDNA standard that was slightly smaller than the target 
eDNA and that was amplified with the same primer pair as 
efficiently as the target eDNA (own data not shown) was used 
[22]. 
When wild-type cDNA was amplified by PCR in the pres- 
ence of increasing amounts of internal standard cDNA 
(0.001-1000 amol), both competed for the oligonucleotide pri- 
mers according to their molar ratio in the reaction mix (Fig. 
2). At a high molar excess of the internal standard cDNA, 
essentially only the standard was amplified by PCR, while 
only the wild-type cDNA was amplified when present in 
high molar excess. When both cDNAs were present in equi- 
molar amounts, both products were formed in equal intensity. 
Thus, the initial amount of wild-type cDNA could be quanti- 
tated by determining the amount of internal standard that 
resulted in the same amount of PCR product as the wild- 
type cDNA. 
EP4 receptor mRNA was present in all cell lines in similar 
amounts of about 5 amol in the PCR reaction mix (Fig. 2). In 
U-937 cells, mRNA for the EP2 receptor amounted to about 
0.05 amol; it was 100-fold less abundant than the EP4 recep- 
tor mRNA (Fig. 2). Given the final specific activity of 
[aSS]dATP of 1 gCi/20 nmol dATP in the RT reaction and 
an estimated average length of mRNA of 2500 nt, 1 mol of 
cDNA equalled roughly 7× 1016 decays per minute (DPM). 
From the RT reaction aliquots of 1000 DPM representing 
lAX  10 -14 mol cDNA were used in the PCR reaction. Since 
5 amol of EP4R specific cDNA was present, it can be con- 
cluded that about 1 in every 2900 mRNA molecules coded for 
the EP4 receptor in Jurkat, KM-3 and U-937 and hence in U- 
Jurkat, EP4 
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Fig. 2. Quantitation of eDNA for the EP2 and EP4 receptors in 
Jurkat, KM-3 and U-937 cells by competitive PCR. Equal amounts 
of eDNA were coamplified with a 10-fold dilution series (1000- 
0.001 amol) of the internal standards for the EP2 and EP4 receptor. 
The arrows denote the point of equimolarity between wild-type 
eDNA (wt) and internal standard (std). Data shown are representa- 
tive of 3 experiments. 
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Fig. 3. Increase in cyclic AMP by PGE2 and its inhibition by the 
EP4R specific antagonist AH23848 in plasma membranes of Jurkat, 
KM-3 and U-937 cells. Cell membranes were prepared by ultracen- 
trifugation. Aliquots representing 25I.tg of membrane protein were 
incubated with the indicated concentrations of PGE2 alone or in the 
presence of 25 gM of AH23848. Values are means + S.E. of 4 inde- 
pendent experiments. 
937 cells only 1 in every 290 000 mRNA molecules coded for 
the EP2 receptor. 
Although the correlation between the number of mRNA 
molecules and the corresponding receptor is not necessarily 
linear due to possible differences in translational efficiencies 
and posttranslational modifications, fewer EP2 than EP4 re- 
ceptors can be expected on U-937 cells. Since the Gs-linked 
EP2 receptor has a lower affinity for PGE2 than the Gs-linked 
EP4 receptor, this would implicate a high number of the high 
affinity EP4 receptor (K,l 1-2 nM [18,23]) and a small number 
of the low affinity EP2 receptor (Kd 100 nM [19]). This con- 
trasts with findings of a highly abundant low affinity (Kd 137 
nM) and a rare high affinity (Kd 3.1 nM) PGEz receptor on 
U-937 cells [24]. Another study reported that the main PGE2 
receptor ( > 90%) on U-937 cells is a high affinity (K,~ 2.9 nM) 
Gi-linked EP3 subtype receptor [16]. In Scatchard plots, this 
group could not detect he other binding site of the Gs-linked 
EP4 subtype receptor, which had been detected by functional 
studies and Western blot, and thereby confirm previous re- 
ports for monocytes [13]. Since multiple PGE2 receptor sub- 
types seem to be present on the same cell type, the differentia- 
tion by binding studies appears to be impossible. 
3.3, Functional PGE2 receptors of the EP4 subtype on human 
mononuclear cell lines 
The presence of EP4 receptor mRNA in a human B-, T- 
lymphocytic and a monocytic ell line is in accordance with 
functional studies. In all three cell lines, PGE2 increased 
cAMP (Fig. 3). This increase in cAMP was inhibited by the 
EP4 specific antagonist AH23848. This antagonist was initi- 
ally described as a competitive antagonist of PGE2 at EP4 
receptors with low affinity (pA2 5.36) but high selectivity 
[25]. In Jurkat, KM-3 and U-937 cell membranes, however, 
it did not behave as a true competitive antagonist. This is in 
line with previous findings in Jurkat cells [26] that led to the 
postulation of a new EP4 receptor elated subtype with a 
different pharmacological profile. The reason for this discrep- 
ancy is as yet unclear, but the present study confirms at least 
the presence of mRNA for the published EP4 receptor in 
Jurkat, KM-3, U-937 and other human B- and T-lymphocytic 
cell lines such as CEM, HUT78, Raji, Daudi, Wi-L2 and 
H2LCL (own data not shown, see above). Certainly, a neu- 
tralizing antibody against he cloned EP4 receptor could shed 
more light on this matter. 
PGE2 can induce apoptosis in mononuclear cells in vitro as 
well as in vivo under various conditions [8,9,27,28], although 
it has also been reported to suppress activation-induced apop- 
tosis [10]. In murine B-cell lines, a dose-dependent growth 
inhibition of immature cells was reported, whereas mature 
cell lines were less susceptible [20]. However, in the present 
study, immature KM-3 cells as well as Jurkat and U-937 cells 
were only inhibited by PGE2 at doses as high as 10 4 M (data 
not shown). Inhibition was most pronounced in U-937 cells 
(87%) and less in KM-3 (73%) and Jurkat (50%) cells. 
3.4. Conclusions 
This study demonstrated the presence of the mRNA for the 
EP4 subtype prostaglandin E2 receptor in Jurkat, KM-3 and 
U-937 cells, mRNA for the EP2 receptor was present only in 
U-937 cells and 100-fold less abundant than EP4 receptor 
mRNA. All cell lines responded to stimulation with PGE2 
with a similar increase in cAMP formation, which was inhib- 
ited by AH23848. Therefore, the EP2 receptor appeared to 
play, if any, only a minor role in mediating the PGE2-stimu- 
lated cAMP increase in human mononuclear cells. In contrast 
to murine mononuclear cell lines, PGE2 did not inhibit pro- 
liferation in Jurkat, KM-3 or U-937 cells. 
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